Who is Yuchun Lee and why was he appointed?

Yuchun Lee was appointed as a Class III Director to Vertex Pharmaceuticals' Board of Directors. The filing does not provide specific details on Mr. Lee's professional background, but his appointment is considered significant enough to be reported via an 8-K filing, suggesting he brings valuable expertise or perspective to the board.

What does it mean for a director to be considered 'independent'?

An independent director is a board member who does not have a material relationship with the company outside of their board service. This independence is crucial for good corporate governance, as it allows the director to make objective decisions in the best interest of all shareholders, free from potential conflicts of interest.

What is the compensation provided to Yuchun Lee?

Mr. Lee will participate in Vertex Pharmaceuticals' standard non-employee director compensation program. This includes a stock option grant for 30,000 shares of common stock with an exercise price of $57.27, which vests over time as per the program's terms.

What is the significance of the stock option grant?

The stock option grant aligns Mr. Lee's interests with those of other shareholders. By having the opportunity to purchase shares at a set price, his financial success as a director is tied to the company's stock performance. This is a common practice to incentivize and reward board members.

VRTX 8-K: Leadership Changes

Summary

Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K report on September 20, 2012, to announce a change in its board of directors. Specifically, the company elected Yuchun Lee as a Class III Director, effective September 14, 2012. Mr. Lee's directorship is set to conclude at the 2013 annual shareholders meeting. The company stated that Mr. Lee meets the independence requirements as defined by both the SEC and NASDAQ. As part of his onboarding, Mr. Lee was granted an option to purchase 30,000 shares of Vertex common stock at an exercise price of $57.27, consistent with the company's non-employee director compensation program.

Key Highlights

1Yuchun Lee appointed as a Class III Director to the Board of Directors, effective September 14, 2012.
2Mr. Lee's current term as director will expire at the 2013 annual shareholders meeting.
3The Board has determined that Mr. Lee qualifies as an independent director under SEC and NASDAQ rules.
4Mr. Lee will receive compensation under the company's non-employee director compensation program.
5On September 14, 2012, Mr. Lee was granted an option to purchase 30,000 shares of common stock.
6The exercise price for the stock option is $57.27 per share.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Sep 20, 2012)

Summary

Key Highlights

Frequently Asked Questions